Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases
Multitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases. This is very useful for multifactorial disease...
Saved in:
Main Authors: | Eleftheria-Emmanouela Katsoulaki, Dimitrios Dimopoulos, Dimitra Hadjipavlou-Litina |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/18/6/831 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Microbiome Dysbiosis as a Driver of Neurodegeneration: Insights into Alzheimer’s and Parkinson’s Diseases
by: Ana Jagodic, et al.
Published: (2025-04-01) -
Atypical course of Parkinson’s disease with clinical manifestations of Huntington’s disease in a patient with an allele of 27 CAG repeats in the HTT gene
by: M. A. Nikitina, et al.
Published: (2021-01-01) -
Decoding the role of large heat shock proteins in the progression of neuroinflammation‐mediated neurodegenerative disorders
by: Shailendra K. Saxena, et al.
Published: (2025-03-01) -
H<sub>2</sub>S IN THE NEURODEGENERATION: A «DOUBLE-FACED JANUS»
by: E. E. Kolesnikova
Published: (2019-11-01) -
Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease
by: Israa J. Hakeem, et al.
Published: (2025-05-01)